Ms Allen joins the Zenas Board of Directors with more than 20 years of experience leading finance, investor relations, business development, human resources, operations and IT at global public and private biotechnology companies.
“We are pleased to welcome Patty to our Board of Directors,” said Lonnie Moulder, founder and Chief Executive Officer of Zenas BioPharma.
“She has successfully led cross-organisational functions and served on the board of directors of both private and public global biotechnology companies."
"We look forward to Patty’s contributions to the next phase of Zenas’ growth as we advance our mission to develop and commercialize transformative immunology-based therapies for patients in need.”
“I look forward to collaborating with the experienced Zenas team and Board of Directors, who are building a leading of inflammation and immunology-focused global biopharmaceutical company through disciplined pipeline execution and business development,” said Ms Allen.
“This is an exciting time for Zenas as they seek to progress multiple programmes through the clinic to ultimately improve the lives of those living with autoimmune diseases.”
Ms Allen most recently served as the Chief Financial Officer at Vividion Therapeutics, from where she recently retired. While at Vividion, she co-led led fundraising and the company’s acquisition by Bayer AG, as the company grew and advanced multiple programmes towards the clinic.
She currently serves on the board of directors and as chair of the audit committee of Deciphera Pharmaceuticals, SwanBio Therapeutics and Anokion, in addition to holding past board member and audit committee chair roles at Inversago Pharma and Yumanity Therapeutics.
